Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

Abstract Disease Overview Chronic lymphocytic leukemia (CLL) is the commonest leukemia
in western countries. The disease typically occurs in elderly patients and has a highly …

Disease overview Chronic lymphocytic leukemia (CLL) is the commonest leukemia in
western countries. The disease typically occurs in elderly patients and has a highly variable …

Once a rarely used subset of medical treatments, protein therapeutics have increased
dramatically in number and frequency of use since the introduction of the first recombinant …

Disease overview: Chronic lymphocytic leukemia (CLL) is the commonest leukemia in
western countries. The disease typically occurs in elderly patients and has a highly variable …

Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20,
was the first monoclonal antibody to be approved for therapeutic use. Treatment with …

The field of chronic lymphocytic leukemia (CLL) has witnessed considerable change since
the time clinical staging was introduced in clinical practice in 1975. Over the years, the …

Purpose Fludarabine and cyclophosphamide (FC), which are active in treatment of chronic
lymphocytic leukemia (CLL), are synergistic with the monoclonal antibody rituximab in vitro …

Anti-CD20 antibody immunotherapy effectively treats non-Hodgkin's lymphoma and
autoimmune disease. However, the cellular and molecular pathways for B cell depletion …

Rituximab is an anti-CD20 chimeric mAb effective for the treatment of B-NHL. It can lyse
lymphoma cells in vitro through both C-and Ab-dependent cellular cytotoxicity. The …